Diabetes complications articles from across Nature Portfolio

Reducing the competitive advantage conferred by driver mutations can abrogate expansions of mutant clones in healthy tissue in mice. This suggests ways to prevent cancer and other diseases that are associated with somatic mutations in humans.

Mechanistic and clinical data indicate that DNA damage contributes to the pathogenesis and progression of diabetic complications. Thus, DNA damage and its signalling are entering the field of diabetology.

Gene therapy holds tremendous promise for treating a wide range of hereditary and acquired diseases by delivering exogenous therapeutic nucleotide sequences into specific cells or tissues. Recent advances support the notion that gene therapy could offer a long-term cure for diabetes mellitus, something that current conventional pharmacotherapies cannot achieve.

We introduced time-based metrics to analyze multiple long-term condition (MLTC) combinations of two or more conditions that include diabetes, among adults in England. We calculated the median age of MLTC onset and years of life lived with and lost to the MLTC, and examined MLTC burdens from both individual perspectives and community perspectives.

Glucagon-like peptide 1 receptor agonists improve glucose control, promote weight loss and reduce the risk of major cardiovascular events in people with type 2 diabetes mellitus. The FLOW study now provides unequivocal evidence of kidney protective effects with semaglutide in adults with type 2 diabetes mellitus and chronic kidney disease.